Site is Being Upgraded

Carbon monoxide-based therapy for autoimmune diabetes (TIDM): Carbon monoxide (CO) releasing molecules-2 (COR-M2) increases the expression of PD-L1, augments Tregs function, promotes immune tolerance, increases pancreatic β-cell proliferation and regeneration, increases insulin secretion, improves insulin sensitivity, increases energy utilization, and reverses TIDM, via up regulation of its target gene, 13/June/2018, 9.23 am

Optimal sleep is required to lead a diabetics-free life: Melatonin-based therapy for diabetes (TIIDM): Melatonin [N-acetyl-5-methoxy tryptamine], a hormone that regulates sleep and wakefulness, increases GLP1R and Caveolin-1 (CAV-1) expression, promotes glucose-induced insulin secretion, improves insulin sensitivity, increases energy utilization, promotes weight loss and protects from diet-induced obesity and TIIDM, via up regulation of its target gene, 13/June/2018, 8.29 am
June 13, 2018
Lifespan extension therapy: Epidermal growth factor (EGF) may increase life span via up-regulation of its target gene BubR1, 14/June/2018, 11.08 pm
June 14, 2018
Show all

Introduction: What they say

A study from the International Center for T1D, Pediatric Clinical Research Center Romeo ed Enrica Invernizzi, “L. Sacco” Department of Biomedical and Clinical Sciences, University of Milan, Milan 20157, Italy; and Nephrology Division, Boston Children’s Hospital, Harvard Medical School, Boston, MA 02115, USA shows that “PD-L1 genetic overexpression or pharmacological restoration in hematopoietic stem and progenitor cells reverses autoimmune diabetes.” This research paper was published, in the 15 November 2017 issue of the journal “Science Translational Medicine” [One of the best research journals in Science with an I.F of 15 plus], by Prof. Fiorina P and Nasr MB and others.


What we say:

On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: Carbon monoxide-based therapy for autoimmune diabetes (TIDM): Carbon monoxide (CO) releasing molecules-2 (COR-M2) increases the expression of PD-L1, augments Tregs function, promotes immune tolerance, increases pancreatic β-cell proliferation and regeneration, increases insulin secretion, improves insulin sensitivity, increases energy utilization, and reverses TIDM, via up regulation of its target gene

[easy_payment currency=”USD”]


From significance of the study to public health relevance:

Given that: (1) more than 422 million people worldwide are affected by Diabetes mellitus (DM); (2) Type 1 Diabetes (T1DM) constitutes about 5-10% (11 to 12 million) of all diabetic cases; (3) the incidence of T1DM is exponentially increasing year after year by 3%; (4) Diabetes is going to be one of the top 10 causes of death by 2030; (5) the life-long painful injection/drug treatment is required to treat DM; (6) the global economic cost spent for diabetes treatment in 2014 was little more than 600 billion US dollars, while treatment for T1DM costs about $15 billion dollars per annum, there is an urgent need to find: (i) a way to induce regeneration of adult ß-cells that were lost in DM;(ii) a side-effect-free natural product-based drug that does not harm or deplete adult stem cells; and (iii) a way to cure, not just treat, diabetes.


What is known?

Prof. Fiorina’s research team has recently shown that:(1) programmed death ligand 1 (PD-L1), the immune checkpoint regulator, is expressed poorly in hematopoietic stem and progenitor cells (HSPCs) of Type-1 diabetic (T1D) patients; (2) PD-L1 inhibits activated T-cells and thereby promotes immune tolerance; (3) the expression of PD-L1 is controlled by a network of miRNAs; (4) attenuating the expression of one of the miRNAs that target PD-L1 restores the expression of PD-L1 in HSPCs; (5) increasing the expression of PD-L1 in HSPCs, either genetically or pharmacologically, inhibits autoimmune response and reverses autoimmune diabetes; and (6) PD-L1 is expressed poorly in human HSPCs of T1D patients, suggesting that increasing the expression of PD-L1 in T1D patients may reverse and cure T1D.


From research findings to Therapeutic opportunity:

This study suggests a carbon monoxide-based therapy for autoimmune diabetes (TIDM).  Carbon monoxide  has been found to be useful in the treatment of a number of diseases, including diabetes. However, the mechanism of action remains unknown.

This study suggests, for the first time, that  Carbon monoxide (CO) releasing molecules-2 (COR-M2), by increasing the expression of its target gene, it may increase the expression of PD-L1. Thereby, it may: (1) increase Regulatory T-cells(Tregs) function; (2) decrease immune activation; (3) increase pancreatic-β-cell proliferation and regeneration; (4) increase expression of genes that promote insulin sensitivity and insulin secretion;(4) decrease metabolic stress; and (5) promote glucose homeostasis (Fig.1).Thus, COR-M2, either alone or in combination with other drugs, may be used to treat TIDM (Fig.2.).

Figure 1. Mechanistic insights into how  COR-M2 inhibits  the development of autoimmune diabetes. COR-M2, by increasing the expression of its target genes, it may increase the expression of PD-L1 and other anti-diabetic genes. Thereby, it may prevent immune activation and attenuate the development of T1DM

Figure 2.  COR-M2 functions as an anti-diabetic agent by up regulating the expression of PD-L1 and other anti-diabetic genes.

 

 

 

 

 

 

 

 

 

 

 


Details of the research findings:

Idea Proposed/Formulated (with experimental evidence) by: Dr L Boominathan Ph.D.

Undisclosed information: How does COR-M2 increase the expression of PD-L1?

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

Amount: $750#

# Research cooperation

For purchase and payment details, you may reach us at info@genomediscovery.org


References:

Web: http://genomediscovery.org or http://newbioideas.com

Citation: Boominathan, L., Carbon monoxide-based therapy for autoimmune diabetes (TIDM): Carbon monoxide (CO) releasing molecules-2 (COR-M2) increases the expression of PD-L1, augments Tregs function, promotes immune tolerance, increases pancreatic β-cell proliferation and regeneration, increases insulin secretion, improves insulin sensitivity, increases energy utilization, and reverses TIDM, via up regulation of its target gene, 13/June/2018, 9.23 am, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org

Courtesy: When you cite, drop us a line at info@genomediscovery.org

Comments are closed.